Healthcare · Biotechnology · NYSE
| Market cap | $1.01B |
|---|---|
| Trailing P/E | — |
| Price / book | — |
| Price / sales | — |
| FCF yield | — |
| Dividend yield | — |
| Gross margin | — |
| Operating margin | — |
| Net margin | — |
| Revenue growth (YoY) | — |
| Revenue growth (3-yr annual) | — |
| EPS growth (YoY) | — |
| FCF/share growth (YoY) | — |
| Beta | — |
| Exchange | NYSE |
| Sector | Healthcare |
| Industry | Biotechnology |
Median target $7.00 from 2 analysts, ranging $5.00 – $9.00.
| Ticker | Company | Market cap | P/E |
|---|---|---|---|
| VRTX | Vertex Pharmaceuticals Incorporated | $127.62B | 26.5 |
| MRNA | Moderna Inc | $81.13B | — |
| REGN | Regeneron Pharmaceuticals, Inc. | $74.79B | 15.4 |
| ARGX | argenx SE | $56.77B | 35.1 |
| RVMD | Revolution Medicines, Inc. | $44.51B | — |
| ONC | BeOne Medicines AG | $41.14B | 63.7 |
| RPRX | Royalty Pharma plc | $32.74B | 10.8 |
| ALNY | Alnylam Pharmaceuticals, Inc. | $29.42B | 27.6 |